RT Journal Article
T1 The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
A1 Gayarre, Javier
A1 Kamieniak, Marta M
A1 Cazorla-Jiménez, Alicia
A1 Muñoz-Repeto, Ivan
A1 Borrego, Salud
A1 García-Donas, Jesús
A1 Hernando, Susana
A1 Robles-Díaz, Luis
A1 García-Bueno, José M
A1 Ramón Y Cajal, Teresa
A1 Hernández-Agudo, Elena
A1 Heredia Soto, Victoria
A1 Márquez-Rodas, Ivan
A1 Echarri, María José
A1 Lacambra-Calvet, Carmen
A1 Sáez, Raquel
A1 Cusidó, Maite
A1 Redondo, Andrés
A1 Paz-Ares, Luis
A1 Hardisson, David
A1 Mendiola, Marta
A1 Palacios, José
A1 Benítez, Javier
A1 García, María José
K1 6q24-26 Deletion
K1 Cisplatin-Sensitivity
K1 DNA Repair
K1 GTF2H5
K1 Ovarian Epithelial Cancer
K1 Survival
AB We aimed to evaluate the prognostic and predictive value of the nucleotide excision repair-related gene GTF2H5, which is localized at the 6q24.2-26 deletion previously reported by our group to predict longer survival of high-grade serous ovarian cancer patients. In order to test if protein levels of GTF2H5 are associated with patients' outcome, we performed GTF2H5 immunohistochemical staining in 139 high-grade serous ovarian carcinomas included in tissue microarrays. Upon stratification of cases into high- and low-GTF2H5 staining categories (> and ≤ median staining, respectively) Kaplan-Meier and log-rank test were used to estimate patients' survival and assess statistical differences. We also evaluated the association of GTF2H5 with survival at the transcriptional level by using the on-line Kaplan-Meier plotter tool, which includes gene expression and survival data of 855 high-grade serous ovarian cancer patients from 13 different datasets. Finally, we determined whether stable short hairpin RNA-mediated GTF2H5 downregulation modulates cisplatin sensitivity in the SKOV3 and COV504 cell lines by using cytotoxicity assays. Low expression of GTF2H5 was associated with longer 5-year survival of patients at the protein (hazard ratio [HR], 0.52; 95% CI, 0.29 to 0.93; p=0.024) and transcriptional level (HR, 0.80; 95% CI, 0.65 to 0.97; p=0.023) in high-grade serous ovarian cancer patients. We confirmed the association with 5-year overall survival (HR, 0.55; 95% CI, 0.38 to 0.78; p=0.0007) and also found an association with progression-free survival (HR, 0.72; 95% CI, 0.54 to 0.96; p=0.026) in a homogenous group of 388 high-stage (stages III-IV using the International Federation of Gynecology and Obstetrics staging system), optimally debulked high-grade serous ovarian cancer patients. GTF2H5-silencing induced a decrease of the half maximal inhibitory concentration upon cisplatin treatment in GTF2H5-silenced ovarian cancer cells. Low levels of GTF2H5 are associated with enhanced prognosis in high-grade serous ovarian cancer patients and may contribute to cisplatin sensitization.
YR 2015
FD 2015-11-27
LK http://hdl.handle.net/10668/10405
UL http://hdl.handle.net/10668/10405
LA en
DS RISalud
RD Jul 7, 2025